How do you define remission? (Q35030854)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

review article

1 reference

title

How do you define remission? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Y Lecrubier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

Acta psychiatrica Scandinavica. Supplementum

16 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

issue

415

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

page(s)

7-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

Cognitive behavioral treatment of residual symptoms in primary major depressive disorder

16 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Residual symptoms in depressed patients who respond acutely to fluoxetine.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Residual symptoms after partial remission: an important outcome in depression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Treatments of depression and the functional capacity to work.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

MAOI treatment response: multiaxial assessment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Treatment Effects on the Social Adjustment of Depressed Patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

The effects of venlafaxine on social activity level in depressed outpatients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Depressive relapses and incomplete recovery from index episode

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Causal estimation of time-varying treatment effects in observational studies: application to depressive disorder.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Efficacy of venlafaxine in depressive illness in general practice

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.106.S415.2.X

7 January 2021

10.1034/J.1600-0447.106.S415.2.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12492767%20AND%20SRC:MED&resulttype=core&format=json